Brian Jonas, PhD
Hematology & Oncology · Sacramento, CANPI 1558542209
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $106,829 of the $116,588 with a category attached, or 91.6%. 16 manufacturers reported payments, led by AbbVie at 48.0% of the total. Reporting peaked in 2022 at $29,365 and has fallen 67.5% since, to $9,554 in 2025. Among hematology & oncology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 79 payments — averaging $1475.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$56K
- Gilead$11K
- Genentech USA, Inc.$10K
- Rigel Pharmaceuticals, Inc.$9K
- Daiichi Sankyo Inc.$6K
- Takeda Pharmaceuticals U.S.A., Inc.$6K
- plus $19K from 10 others
Across 353 payments — averaging $20,226 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$3.6M
- Pharmacyclics LLC, An Abbvie Company$1.4M
- Jazz Pharmaceuticals Inc.$977K
- Amgen$505K
- Genentech, Inc.$311K
- Incyte Corporation$85K
- plus $254K from 6 others
What the payments were for
- Consulting fees$106,82992%
- Speaking & faculty fees$7,2126%
- Travel & lodging$1,0231%
- Food & beverage$1,5071%
- Education$170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 39 | $55,924 |
| Gilead | 7 | $10,800 |
| Genentech USA, Inc. | 7 | $9,787 |
| Rigel Pharmaceuticals, Inc. | 7 | $9,098 |
| Daiichi Sankyo Inc. | 3 | $5,805 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $5,700 |
| Pfizer | 2 | $4,250 |
| E.r. Squibb & Sons, L.L.C. | 2 | $4,249 |
| Servier Pharmaceuticals LLC | 1 | $3,740 |
| Bristol Myers Squibb | 2 | $2,962 |
| Jazz Pharmaceuticals Inc. | 1 | $2,500 |
| Genentech, Inc. | 1 | $1,375 |
| Secura Bio, Inc. | 1 | $184 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $125 |
| Janssen Scientific Affairs, LLC | 1 | $73 |
| Stemline Therapeutics Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$116,588 in reported general payments places this provider in the 90th percentile of 1,363 hematology & oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IdhifaEnasidenib Mesylate | 40 | $1,324,930 |
| IclusigPonatinib Hcl | 36 | $699,457 |
| TibsovoIvosidenib | 17 | $562,963 |
| RezlidhiaOlutasidenib | 12 | $387,277 |
| SprycelDasatinib | 37 | $338,804 |
| BosulifBosutinib | 17 | $297,758 |
| TasignaNilotinib Hcl | 14 | $272,290 |
| JakafiRuxolitinib Phosphate | 16 | $267,875 |
| VenclextaVenetoclax | 63 | $254,897 |
| BesremiRopeginterferon Alfa-2b-Njft | 15 | $249,976 |
| ImbruvicaIbrutinib | 14 | $214,758 |
| CresembaIsavuconazonium Sulfate | 25 | $150,146 |
| Imatinib Mesylate | 28 | $94,156 |
| NivestymFilgrastim-Aafi | 11 | $13,635 |
| Cefpodoxime Proxetil | 16 | $2,585 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbIdhifa | $2,962 | $1,324,93040 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Iclusig | $5,700 | $699,45736 claims |
| Servier Pharmaceuticals LLCTibsovo | $3,740 | $562,96317 claims |
| Rigel Pharmaceuticals, Inc.Rezlidhia | $9,098 | $387,27712 claims |
| E.r. Squibb & Sons, L.L.C.Sprycel | $4,249 | $338,80437 claims |
| PfizerBosulif, Nivestym | $4,250 | $311,39428 claims |
| AbbVieVenclexta | $55,924 | $254,89763 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $125 | $214,75814 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,363 hematology & oncology providers in California.
Other hematology & oncology in Sacramento
- Nitin RohatgiSacramento$814K
- Mehrdad AbediSacramento$613K
- Adam GiermaszSacramento$438K
- Scott ChristensenSacramento$349K
- David GandaraSacramento$336K
- Joseph TuscanoSacramento$258K
- Dennis SlamonLos Angeles$3.1M
- Sandra HorningStanford$2.5M
- Mohammadbagher ZiariCorona$2.5M
- George YaghmourLos Angeles$1.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.